Understanding the new and evolving profile of adverse drug effects in schizophrenia.
This article has reviewed the emerging side-effect profiles of second-generation antipsychotic medications. Although these medications have favorable extrapyramidal side-effect profiles, clinicians must be aware of their propensity to cause weight gain, glucose and lipid abnormalities, and cardiac and sexual side effects. If clinicians are proactive about warning patients about these side effects and appropriately monitoring them, further morbidity and mortality may be prevented in this patient population. Initial choices of medication should be made based on the relative side-effect profiles in light of a particular patient's medical status. In the future, new treatments may be developed, with even fewer side effects.
Wirshing
Donna A
DA
Department of Psychiatry, Schizophrenia Treatment Unit, Veterans Administration West Los Angeles Healthcare Center, 11301 Wilshire Boulevard, Building 210, Room 15, Los Angeles, CA 90073, USA. ames@ucla.edu
Pierre
Joseph M
JM
Erhart
Stephen M
SM
Boyd
Jennifer A
JA
D014150:Antipsychotic Agents / Q000009:adverse effects*; D003920:Diabetes Mellitus / Q000139:chemically induced; D005260:Female; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced; D008133:Long QT Syndrome / Q000139:chemically induced; D008297:Male; D011388:Prolactin / Q000378:metabolism; D012559:Schizophrenia / Q000145:classification* / Q000188:drug therapy*; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced; D015430:Weight Gain / Q000187:drug effects
D014150:Antipsychotic Agents; D011388:Prolactin; D005947:Glucose